{"organizations": [], "uuid": "d0897a0344b25c9782fcd2fd40795e1c11b18ccf", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/3", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/27/pr-newswire-mergenet-solutions-inc-extends-dividend-claim-deadline.html", "country": "US", "domain_rank": 767, "title": "Mergenet Solutions, Inc., Extends Dividend Claim Deadline", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-27T16:35:00.000+03:00", "replies_count": 0, "uuid": "d0897a0344b25c9782fcd2fd40795e1c11b18ccf"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/27/pr-newswire-mergenet-solutions-inc-extends-dividend-claim-deadline.html", "ord_in_thread": 0, "title": "Mergenet Solutions, Inc., Extends Dividend Claim Deadline", "locations": [], "entities": {"persons": [], "locations": [{"name": "fla.", "sentiment": "none"}, {"name": "deerfield beach", "sentiment": "none"}, {"name": "fl.", "sentiment": "none"}, {"name": "florida", "sentiment": "none"}, {"name": "coconut creek", "sentiment": "none"}], "organizations": [{"name": "mergenet solutions, inc.", "sentiment": "neutral"}, {"name": "mergenet solutions, inc", "sentiment": "none"}, {"name": "innomed healthscience, inc.", "sentiment": "none"}, {"name": "mergenet solutions", "sentiment": "none"}, {"name": "mergenet medical, inc.", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DEERFIELD BEACH, Fla., March 27, 2018 /PRNewswire/ -- Mergenet Solutions, Inc., an award winning Medical Technology Business Incubator, located in Deerfield Beach, Fl., has announced it will extend its shareholder dividend claim deadline. Mergenet Solutions, Inc. currently Incubates such companies as Innomed Healthscience, Inc., who's flagship product in development is expected to address OSA, COPD as well as other modalities and Mergenet Medical, Inc. who's flagship product in development includes High Flow Oxygen Therapy with Pressure Monitoring.\nThe deadline has been extended through June 15, 2018. Forms may be obtained from the company or company's stock transfer agent.\nAbout Mergenet Solutions, Inc.\nMergenet Solutions is an established American enterprise with worldwide reach from an executive home base in Coconut Creek, Florida. By functioning as a full-service technology incubator, our organization identifies, assists and invests in new and emerging companies in several promising sectors. Firms at the core of our existing portfolio are involved in cutting-edge advances in technology and breakthrough medical solutions. Learn more at www.mergenetsolutions.com\nAbout Innomed Healthscience, Inc:\nInnomed Healthscience ,a medical technology development company, develops and manufactures a patented new technology to provides comfortable OSA treatment for mild to moderate patients requiring positive ventilation therapy without the use of machines, electricity, tubing, noise, or masks. Currently in clinical trial phase, the new small nasal unit will be a viable option for sleep apnea sufferers the world over. Innomed Healthscience is also developing products for the treatment of COPD.\nAbout Mergenet Medical, Inc.:\nMergenet Medical has filed a number of patents for its HiFLO2 line of products and plans to file additional applications as development dictates. HiFLO2 is compact and self-contained, and the disposable accessories can be easily assembled and disassembled in minutes, all using simple single push or pull connections. Our device utilizes a very clean air path, which is filtered and then sent along a sealed path to the patient. The HiFLO2 series' simple design also enables caregivers to easily control, monitor and record vital statistics such as upper airway pressure, temperature, humidity, respiratory rates and flow rates. The HiFlO2 is still in development. Sale of the HiFLO2 series is subject to FDA clearance.\nContact:\nElena Hartmanis\nEMI Group\n561.756.5551\nView original content: http://www.prnewswire.com/news-releases/mergenet-solutions-inc-extends-dividend-claim-deadline-300619440.html\nSOURCE Mergenet Solutions, Inc.", "external_links": ["http://www.prnewswire.com/news-releases/mergenet-solutions-inc-extends-dividend-claim-deadline-300619440.html", "http://www.mergenetsolutions.com/"], "published": "2018-03-27T16:35:00.000+03:00", "crawled": "2018-03-27T17:22:01.001+03:00", "highlightTitle": ""}